Azithromycin for mild-to-moderate COVID-19

Detalles Bibliográficos
Autores principales: Patel, Jigar, Berezowski, Ivan, Abdelmonem, Ahmed, Taylor, Dania, Pourmand, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428482/
https://www.ncbi.nlm.nih.gov/pubmed/34509194
http://dx.doi.org/10.1016/S2213-2600(21)00379-9
_version_ 1783750387619069952
author Patel, Jigar
Berezowski, Ivan
Abdelmonem, Ahmed
Taylor, Dania
Pourmand, Ali
author_facet Patel, Jigar
Berezowski, Ivan
Abdelmonem, Ahmed
Taylor, Dania
Pourmand, Ali
author_sort Patel, Jigar
collection PubMed
description
format Online
Article
Text
id pubmed-8428482
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-84284822021-09-10 Azithromycin for mild-to-moderate COVID-19 Patel, Jigar Berezowski, Ivan Abdelmonem, Ahmed Taylor, Dania Pourmand, Ali Lancet Respir Med Correspondence Elsevier Ltd. 2021-10 2021-09-09 /pmc/articles/PMC8428482/ /pubmed/34509194 http://dx.doi.org/10.1016/S2213-2600(21)00379-9 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Correspondence
Patel, Jigar
Berezowski, Ivan
Abdelmonem, Ahmed
Taylor, Dania
Pourmand, Ali
Azithromycin for mild-to-moderate COVID-19
title Azithromycin for mild-to-moderate COVID-19
title_full Azithromycin for mild-to-moderate COVID-19
title_fullStr Azithromycin for mild-to-moderate COVID-19
title_full_unstemmed Azithromycin for mild-to-moderate COVID-19
title_short Azithromycin for mild-to-moderate COVID-19
title_sort azithromycin for mild-to-moderate covid-19
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428482/
https://www.ncbi.nlm.nih.gov/pubmed/34509194
http://dx.doi.org/10.1016/S2213-2600(21)00379-9
work_keys_str_mv AT pateljigar azithromycinformildtomoderatecovid19
AT berezowskiivan azithromycinformildtomoderatecovid19
AT abdelmonemahmed azithromycinformildtomoderatecovid19
AT taylordania azithromycinformildtomoderatecovid19
AT pourmandali azithromycinformildtomoderatecovid19